1. Home
  2. WST vs RPRX Comparison

WST vs RPRX Comparison

Compare WST & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Pharmaceutical Services Inc.

WST

West Pharmaceutical Services Inc.

HOLD

Current Price

$365.55

Market Cap

25.8B

Sector

Health Care

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$57.16

Market Cap

22.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WST
RPRX
Founded
1923
1996
Country
United States
United States
Employees
10800
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8B
22.0B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
WST
RPRX
Price
$365.55
$57.16
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$325.86
$51.40
AVG Volume (30 Days)
674.9K
3.5M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
0.30%
1.90%
EPS Growth
1.49
N/A
EPS
1.92
0.67
Revenue
$2,886,900,000.00
$2,378,193,000.00
Revenue This Year
$6.76
$38.63
Revenue Next Year
$6.22
$4.73
P/E Ratio
$190.59
$86.22
Revenue Growth
1.95
5.06
52 Week Low
$206.80
$34.63
52 Week High
$367.66
$57.79

Technical Indicators

Market Signals
Indicator
WST
RPRX
Relative Strength Index (RSI) 78.53 63.95
Support Level $253.53 $38.07
Resistance Level N/A N/A
Average True Range (ATR) 7.33 1.50
MACD 2.68 0.16
Stochastic Oscillator 95.80 99.55

Price Performance

Historical Comparison
WST
RPRX

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: